Data Year:

For its 2025 fiscal year, IONIS PHARMACEUTICALS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Richard S. Geary
EVP, Chief Development Officer
Total Compensation $3,331,399 View details Pay Rank By Title In Biotechnology industry #79 View more
Brett P. Monia
Chief Executive Officer
Total Compensation $13,350,777 View details Pay Rank By Title In Biotechnology industry #74 View more
Elizabeth L. Hougen
EVP, Finance and Chief Financial Officer
Total Compensation $4,422,302 View details Pay Rank By Title In Biotechnology industry #71 View more
Patrick R. O'Neil
EVP, Chief Legal Officer and General Counsel
Total Compensation $3,210,608 View details Pay Rank By Title In Biotechnology industry #85 View more
Eric Swayze
EVP, Research
Total Compensation $3,233,339 View details Pay Rank By Title In Biotechnology industry #84 View more
Brian Birchler
EVP, Corporate and Development Operations
Total Compensation $3,245,054 View details Pay Rank By Title In Biotechnology industry #82 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at IONIS PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. IONIS PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. IONIS PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Richard S. Geary
EVP, Chief Development Officer
Total Cash $1,283,961 Equity $1,999,607 Other $47,831 $3,331,399
Brett P. Monia
Chief Executive Officer
Total Cash $3,449,825 Equity $9,882,943 Other $18,009 $13,350,777
Elizabeth L. Hougen
EVP, Finance and Chief Financial Officer
Total Cash $1,561,665 Equity $2,817,628 Other $43,009 $4,422,302
Patrick R. O'Neil
EVP, Chief Legal Officer and General Counsel
Total Cash $1,192,992 Equity $1,999,607 Other $18,009 $3,210,608
Eric Swayze
EVP, Research
Total Cash $1,215,723 Equity $1,999,607 Other $18,009 $3,233,339
Brian Birchler
EVP, Corporate and Development Operations
Total Cash $1,197,438 Equity $1,999,607 Other $48,009 $3,245,054
For its 2025 fiscal year, IONIS PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Brett P. Monia CEO Pay $13,350,777 Median Employee Pay $304,680 CEO Pay Ratio 44:1
For its 2024 fiscal year, IONIS PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Allene M. Diaz Total Cash $551,933
B. Lynne Parshall Total Cash $559,933
Joan E. Herman Total Cash $561,933
Joseph H. Wender Total Cash $619,933
Joseph Klein, III Total Cash $371,771
Joseph Loscalzo Total Cash $589,933
Michael J. Yang Total Cash $849,983
Michael R. Hayden Total Cash $549,933
Spencer R. Berthelsen Total Cash $569,933
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.